Our HTGF Portfolio of startups offers excellent opportunities and is always hiring talented people.
CollimateHealth develops a clinically scalable microbeam radiation technology designed to reshape the way cancer is treated. While conventional radiation oncology typically relies on broader and lower-dose beams that cause significant side effects, microbeam radiation delivers an array of extremely narrow, micrometre-scale beams at substantially higher dose. Tumors exposed to microbeam radiation undergo a form of highly disruptive cell death that increases antigen presentation, which helps to activate an immune response against cancer cells beyond the primary irradiated tumour. In addition, the temporary channels created by microbeam irradiation improve the delivery of therapeutics into tumour tissue, creating synergies with both chemotherapy and immunotherapy.